English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Washington University School of Medicine in St. Louis with a therapy designed by WashU Medicine researchers, the trial is the first to report results for this type of vaccine — known as a neoantigen DNA vaccine — for breast cancer patients.
Tag: triple negative breast cancer
Cleveland Clinic Announces Updated Findings in Preventive Breast Cancer Vaccine Study
Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
The study team found that the investigational vaccine was generally well tolerated and produced an immune response in most patients. The team described the side effects of the vaccine, showed the highest tolerated dose to date, and presented the immunologic effects of the vaccine. Findings are being presented at the Society for Immunotherapy of Cancer Annual Meeting.
3 Things to Know After Receiving a Breast Cancer Diagnosis
For Breast Cancer Awareness Month, breast surgeons Katharine A. Yao, MD, FACS, and Daniela A. Ochoa, MD, FACS, of the American College of Surgeons (ACS) share tips on coping with a breast cancer diagnosis.
MD Anderson Research Highlights for July 24, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tip Sheet: Weight loss drugs and cancer prevention, Fred Hutch at AACR, lymphedema Q&A — and new vice president and chief nursing officer
SEATTLE — April 3, 2024 — Below are summaries of recent Fred Hutchinson Cancer Center research findings, patient stories and other news. If you’re covering the American Association for Cancer Research (AACR) Annual Meeting, please see our list of and contact to set up interviews.
MD Anderson Research Highlights for February 21, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson offer insights into drug-drug interactions for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes; patient-derived xenograft models as a viable translational research tool in early-phase clinical trials; a novel gene expression signature to stratify patients with bladder cancer; a potential therapeutic target to overcome treatment resistance in multiple myeloma; a role for mutant p53 in protecting against ferroptosis in triple-negative breast cancer; and diet modifications to improve treatment outcomes in FLT3-mutated AML.
Cleveland Clinic Announces Next Step in Preventive Breast Cancer Vaccine Study
Cleveland Clinic researchers have launched the next step in their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
Expert Available for Comment on Black Women, Breast Cancer and Clinical Trials
While there has been an overall decline in breast cancer deaths over the last 30 years, there is a persistent and significant mortality gap between Black women and white women. Black women are also disproportionately affected by more aggressive subtypes of…
Breast Cancer Research Foundation Renews Support for Mount Sinai Research on Triple-Negative Breast Cancer
The Breast Cancer Research Foundation (BCRF) has renewed its funding to Elisa Port, MD, and Hanna Irie, MD, PhD, to study new therapeutic approaches that target aggressive triple-negative breast cancer. The latest installment of $225,000 brings the total to almost $2 million over the past nine years. It will fund research into the immune microenvironment of triple-negative breast cancer in order to identify new strategies to enhance cancer-fighting immune responses for this aggressive breast cancer, which traditionally has few options for treatment.
How a plant virus could protect and save your lungs from metastatic cancer
Using a virus that grows in black-eyed pea plants, researchers developed a new therapy that could keep metastatic cancers from spreading to the lungs, as well as treat established tumors in the lungs.
Rutgers Cancer Institute of New Jersey Expert Available for Comment on Disparities in Triple-Negative Breast Cancer
New Brunswick, N.J., August 24 2021 – Cancer is a disease that can impact anyone, but it does not impact everyone equally. According to the American Cancer Society, breast cancer is the most commonly diagnosed cancer among Black women, and Black women…
Potential Drug Target for Difficult-To-Treat Breast Cancer: RNA-Binding Proteins
UC San Diego studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers.
Therapeutic resistance linked to softer tissue environment in breast cancer
Researchers at the University of California, San Francisco, have discovered that aggressive, triple-negative breast cancers (TNBCs) can evade treatment by reorganizing and softening the collagen matrix that surrounds the cancer cells. The study, which will be published April 2 in the Journal of Experimental Medicine (JEM), shows that the softer matrix activates a signaling pathway that promotes the cancer cells’ survival, and suggests that targeting this pathway could enhance the effectiveness of chemo- and radiotherapy in TNBC patients.
Cancer Cell Vulnerability Points to Potential Treatment Path for Aggressive Disease
New findings, reported in Nature Communications, describe the discovery of a unique dependence of cancer cells on a particular protein, which could lead to desperately needed treatment for hard-to-treat cancers.
Breast cancer screening by age 40 or younger for Black women advise Beaumont researchers
The physicians focused on how Black women dealt with getting screened and unique issues relevant to them. They revealed their findings recently in the Journal of Breast Imaging in “Breast Cancer Screening Recommendations: African American Women Are at a Disadvantage.”
Disparities in Triple Negative Breast Cancer
Rutgers Cancer Institute expert highlights triple negative breast cancer (TNBC), and aggressive subtype of breast cancer with a high prevalence among younger African American women and those of African descent.
Developing precise medicines for triple negative breast cancer
Taking advantage of a cancer cell’s altered metabolism that drives its runaway growth, Princess Margaret researchers are zeroing in on these molecular changes to help them develop more precise drug targets for one of the most deadly breast cancers.
Immunotherapy extends survival in mouse model of hard-to-treat breast cancer (video)
Today, scientists report a new immunotherapy that extends the survival of mice that have triple negative breast tumors, a difficult-to-treat form of cancer. The researchers will present their results at the American Chemical Society Fall 2020 Virtual Meeting & Expo.
HDAC6 Can Control Tumor Growth and Halt Metastasis in Triple-Negative Breast Cancer
Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the journal Cancer Research by investigators at the GW Cancer Center.
Study Examines Genetic Testing in Diverse Young Breast Cancer Patients over a Decade
Researchers examined racial and ethnic differences in genetic testing frequency and results among diverse breast cancer patients diagnosed at age 50 or younger from January 2007 to December 2017. They found that among 1,503 diverse young breast cancer patients, less than half (46.2 percent) completed hereditary breast and ovarian cancer genetic testing. However, the percentage of women who completed genetic testing increased over time from 15.3 percent in 2007 to a peak of 72.8 percent in 2015.
Researchers Create a Potential Therapy for Deadly Breast Cancer That Has Few Treatment Options
Mount Sinai researchers have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few effective treatment options, according to a study published in Nature Chemical Biology in December.
Aggressive Form of Breast Cancer Influenced by Dual Action of Genes and RNA
Women with an aggressive, less-common type of breast cancer, known as triple-negative, versus a more common form of the disease, could be differentiated from each other by a panel of 17 small RNA molecules that are directly influenced by genetic alterations typically found in cancer cells.